- ImmuCell reported preliminary Q2 2026 product sales of $7.2 million, up 11.5% year over year.
- First-half 2026 product sales increased 20.9% to $17.5 million.
- Domestic sales rose 27.7% in the second quarter, offsetting weaker international performance.
- Sales of Tri-Shield First Defense® increased 8.3% during the quarter, while Dual-Force® and other products grew 19.1%.
- Company leadership cited strong U.S. demand, improved product availability, and expanded commercial efforts targeting dairy producers.
ImmuCell Corporation reported preliminary, unaudited second-quarter product sales that reflected continued momentum for its calf health biologics business, driven by strong domestic demand and increased commercial activity across the U.S. dairy sector.
The company generated approximately $7.2 million in product sales during the second quarter ended June 30, representing an 11.5% increase from the same period in 2025. For the first six months of 2026, preliminary product sales reached $17.5 million, a 20.9% increase compared with the first half of last year.
Domestic growth offsets international decline
ImmuCell said U.S. sales increased 27.7% during the quarter to $6.2 million, benefiting from improved product availability and continued customer demand.
International sales declined 38.9% to $1.0 million compared with the second quarter of 2025. Chief Financial Officer Timothy Fiori noted that the year-over-year comparison was influenced by unusually strong distributor restocking activity during the prior-year period following an extended backlog. He added that the company believes end-user demand remains healthy, particularly in Canada.
For the first six months of 2026, domestic sales increased 32.5%, while international sales were down 35.7% compared with the same period last year.
Calf health portfolio continues to expand
The company’s flagship Tri-Shield First Defense® product generated $4.9 million in second-quarter sales, an increase of 8.3% year over year.
Sales of Dual-Force® and other products increased 19.1% during the quarter as ImmuCell expanded its commercial focus on year-round dairy operations.
President and CEO Olivier te Boekhorst said the company’s commercial team continues to grow its customer base within the dairy segment while benefiting from improved manufacturing capacity and product availability.
Financial results to follow
ImmuCell plans to release its complete unaudited financial results and discuss revenue drivers during a conference call scheduled for August 14, 2026.
The company develops and markets biologic products designed to improve calf health and productivity, including its First Defense® line of colostrum-derived antibodies used to help protect newborn calves against the leading causes of neonatal diarrhea.
Information sourced from the company’s press release.
Forward-Looking Statements: This article summarizes preliminary, unaudited financial information and forward-looking statements made by ImmuCell Corporation. Actual financial results and future performance may differ materially from preliminary estimates and management expectations. Readers should refer to the company’s filings with the U.S. Securities and Exchange Commission for a discussion of risk factors and uncertainties.
